Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates.

ABSTRACT: XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of Staphylococcus aureus in the nasal cavity to prevent post-operative staphylococcal infections. This study reports the minimum inhibitory concentration (MIC) of XF-73 in comparison to 22 antibiotics against a panel of >2,500 clinical isolates composed of 16 different Coagulase-positive and -negative Staphylococcus species from 33 countries. XF-73 was found to be effective against all isolates tested, with MICs ranging between ≤0.12 - 4 µg/ml (MIC₅₀ and MIC₉₀ values of 0.5 and 1 µg/ml respectively). XF-73 was found to be

SUBMITTER: Rhys-Williams W 

PROVIDER: S-EPMC10600368 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature